Skip to main content

Research

Clinical Trials Funded by Drug and Device Companies

Registered clinical trials that drug and device companies funded in 2025, with the U.S. doctors named as investigators and the hospitals and sites where they run. Search by condition, drug, sponsor or trial number.

2,065 trials, most industry funding first

  1. Real-World Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma

    Completed · Relapsed and Refractory Multiple Myeloma (RRMM)

    NCT05673967 · Regeneron Pharmaceuticals, Inc. · 0 U.S. investigators

    $6,000research payments

  2. Artificial Urinary Sphincter Clinical Outcomes

    Completed · Stress Urinary Incontinence

    NCT04088331 · Boston Scientific Corporation · 3 U.S. investigators

    $5,904research payments

  3. SMR Stemless Reverse vs SMR Reverse Shoulder System

    Recruiting · Not applicable · Arthroplasty, Replacement

    NCT04697004 · Encore Medical, LP · 1 U.S. investigator

    $5,864research payments

  4. An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

    Completed · Phase 3 · Advanced Cancer

    NCT02743494 · E.r. Squibb & Sons, L.l.c. · 3 U.S. investigators

    $5,830research payments

  5. Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

    Terminated · Phase 1, Phase 2 · Non-Hodgkin Lymphoma

    NCT05296525 · Gamida Cell Inc. · 1 U.S. investigator

    $5,750research payments

  6. Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor

    Active, not recruiting · Phase 2 · Metastatic Breast Cancer

    NCT02738866 · Menarini Silicon Biosystems, Inc. · 1 U.S. investigator

    $5,744research payments

  7. A Study of LY4167586 in Participants With Obesity or Overweight Who Are Otherwise Healthy

    Active, not recruiting · Phase 1 · Overweight

    NCT07225556 · Eli Lilly and Company · 1 U.S. investigator

    $5,720research payments

  8. Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

    Completed · Phase 3 · Migraine

    NCT06241313 · AbbVie Inc. · 0 U.S. investigators

    $5,673research payments

  9. The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial

    Recruiting · Not applicable · Extubation Failure

    NCT05446272 · Maquet Critical Care Ab · 1 U.S. investigator

    $5,600research payments

  10. SC-004 Alone or With ABBV-181 in Subjects With Epithelial Ovarian, Fallopian Tube, Primary Peritoneal and Endometrial Cancers

    Terminated · Phase 1 · Cancer

    NCT03138408 · AbbVie Inc. · 1 U.S. investigator

    $5,457research payments

  11. A Study of LY3437943 in Postmenopausal Female Participants Who Are Overweight or Obese

    Completed · Phase 1 · Overweight

    NCT06039826 · Eli Lilly and Company · 1 U.S. investigator

    $5,436research payments

  12. Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer

    Completed · Phase 2 · Metastatic Castration-Resistant Prostate Cancer

    NCT04408924 · Eli Lilly and Company · 1 U.S. investigator

    $5,366research payments

  13. Vedolizumab IV in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD)

    Completed · Phase 2 · Ulcerative Colitis

    NCT03138655 · Takeda Pharmaceuticals U.S.A., Inc. · 1 U.S. investigator

    $5,259research payments

  14. Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

    Recruiting · Phase 1, Phase 2 · Hodgkin Lymphoma

    NCT03681561 · E.r. Squibb & Sons, L.l.c. · 1 U.S. investigator

    $5,250research payments

  15. A Study to Assess the Relative Bioavailability of Oral Tavapadon in Healthy Adult Participants

    Completed · Phase 1 · Healthy Volunteer

    NCT06895356 · AbbVie Inc. · 0 U.S. investigators

    $5,210research payments

  16. 18F-Fluciclovine PET-MRI in High-grade Glioma

    Recruiting · Early phase 1 · Glioma

    NCT05553041 · Blue Earth Diagnostics · 1 U.S. investigator

    $5,166research payments

  17. A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy

    Terminated · Not applicable · Brain Metastases

    NCT06015295 · Blue Earth Diagnostics · 1 U.S. investigator

    $5,166research payments

  18. Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

    Completed · Phase 2, Phase 3 · COVID-19

    NCT04315298 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $5,160research payments

  19. Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

    Active, not recruiting · Phase 3 · Breast Ductal Carcinoma In Situ

    NCT01272037 · Menarini Silicon Biosystems, Inc. · 1 U.S. investigator

    $5,131research payments

  20. An Investigational Scan (Flotufolastat F 18 PET/CT) for Detecting Residual or Recurrent Disease in Patients Who Completed Focal Therapy for Prostate Cancer.

    Recruiting · Phase 2 · Prostate Carcinoma

    NCT07185165 · Blue Earth Diagnostics · 1 U.S. investigator

    $5,066research payments

  21. MDR - Biomet Cannulated Screws

    Active, not recruiting · Fractures, Bone

    NCT04002518 · Zimmer Biomet Holdings, Inc. · 3 U.S. investigators

    $5,061research payments

  22. Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

    Completed · Phase 2 · Cutaneous Lupus Erythematosus

    NCT04781816 · Sanofi US Services Inc. · 1 U.S. investigator

    $5,000research payments

  23. Extended Treatment and Follow-up of Subjects Treated With Belumosudil in Study KD025-208 or Study KD025-213

    Completed · Phase 2 · Chronic Graft-versus-host-disease

    NCT05305989 · Sanofi-aventis U.S. LLC · 0 U.S. investigators

    $5,000research payments

  24. Study on Two Adjuvanted Dose Levels of Panblok H7+MF59 Compared for Immunogenicity and Safety With an Unadjuvanted Dose of Panblok H7 in Participants 18 Years of Age and Older

    Completed · Phase 1, Phase 2 · Influenza

    NCT05608005 · Sanofi Pasteur Inc. · 1 U.S. investigator

    $5,000research payments

  25. RESCUE: Discontinuation of GLP-1

    Terminated · Obesity

    NCT07190794 · Boston Scientific Corporation · 1 U.S. investigator

    $5,000research payments

  26. AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis

    Recruiting · Not applicable · Intraventricular Hemorrhage

    NCT05649904 · Irras USA, Inc. · 1 U.S. investigator

    $4,886research payments

  27. A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)

    Completed · Phase 3 · Waldenström's Macroglobulinemia

    NCT03053440 · Beone Medicines USA, Inc. · 1 U.S. investigator

    $4,843research payments

  28. A Study of TAK-079 in Adults With Persistent/Chronic Primary Immune Thrombocytopenia

    Completed · Phase 2 · Primary Immune Thrombocytopenia

    NCT04278924 · Takeda Pharmaceuticals U.S.A., Inc. · 0 U.S. investigators

    $4,800research payments

  29. A Study to Assess Adverse Events and Change in Disease Condition of Mesalamine Capsules in Children Aged 5 to 17 Years With Ulcerative Colitis

    Withdrawn · Phase 3 · Ulcerative Colitis (UC)

    NCT05316220 · AbbVie Inc. · 1 U.S. investigator

    $4,740research payments

  30. A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers

    Terminated · Phase 1 · Acute Myeloid Leukemia (AML)

    NCT04272203 · AbbVie Inc. · 0 U.S. investigators

    $4,724research payments

  31. An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

    Completed · Phase 3 · Hypercholesterolaemia

    NCT03510884 · Sanofi US Services Inc. · 1 U.S. investigator

    $4,578research payments

  32. A Phase 3 Open-label Interventional Study of Intravenous Recombinant Coagulation Factor VIII Fc-von Willebrand Factor-XTEN Fusion Protein, Efanesoctocog Alfa (BIVV001), in Patients With Severe Hemophilia A

    Completed · Phase 3 · Factor VIII Deficiency

    NCT04161495 · Genzyme Corporation · 0 U.S. investigators

    $4,500research payments

  33. A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa

    Completed · Phase 3 · Dystrophic Epidermolysis Bullosa

    NCT04917874 · Krystal Biotech Inc · 1 U.S. investigator

    $4,500research payments

  34. Study to Evaluate the Relative Bioavailability of Two Risankizumab Drug Product Presentations in Healthy Volunteers.

    Completed · Phase 1 · Healthy Volunteers

    NCT05567029 · AbbVie Inc. · 1 U.S. investigator

    $4,487research payments

  35. Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis

    Completed · Phase 4 · Dermatitis Atopic

    NCT04718870 · Genzyme Corporation · 1 U.S. investigator

    $4,482research payments

  36. Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

    Completed · Phase 3 · Advanced Malignancies

    NCT04164199 · Beone Medicines USA, Inc. · 1 U.S. investigator

    $4,458research payments

  37. Chronic Exertional Compartment Syndrome (CECS) Treated With Abobotulinumtoxin A

    Completed · Phase 4 · Compartment Syndrome of Leg

    NCT05466539 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $4,403research payments

  38. Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

    Active, not recruiting · Phase 3 · Non Small Cell Lung Cancer

    NCT04379635 · Beone Medicines (shanghai) Co. Ltd · 1 U.S. investigator

    $4,380research payments

  39. Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

    Recruiting · Phase 2 · Sickle Cell Disease

    NCT07224360 · Csl Behring · 3 U.S. investigators

    $4,374research payments

  40. Anovo™ Surgical System - Registry Study

    Status unknown · GYN Disorders

    NCT05945433 · Momentis Surgical Inc. · 1 U.S. investigator

    $4,322research payments

  41. A Study of LY3209590 in Participants With Type 2 Diabetes Mellitus

    Completed · Phase 2 · Type 2 Diabetes Mellitus

    NCT03736785 · Eli Lilly and Company · 5 U.S. investigators

    $4,287research payments

  42. Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

    Recruiting · Phase 2 · Grade 3b Follicular Lymphoma

    NCT05890352 · Ipsen Biopharmaceuticals, Inc · 1 U.S. investigator

    $4,265research payments

  43. FlowTriever All-Comer Registry for Patient Safety and Hemodynamics

    Completed · PE - Pulmonary Embolism

    NCT03761173 · Stryker Corporation · 2 U.S. investigators

    $4,260research payments

  44. Gene Delivery Clinical Trial of SRP-9003 (Bidridistrogene Xeboparvovec) for Participants With Limb-Girdle Muscular Dystrophy, Type 2E (LGMD2E) (Beta-Sarcoglycan Deficiency)

    Terminated · Phase 1, Phase 2 · Limb-Girdle Muscular Dystrophy, Type 2E

    NCT03652259 · Sarepta Therapeutics, Inc. · 0 U.S. investigators

    $4,200research payments

  45. Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

    Completed · Conjunctivitis

    NCT04287608 · Regeneron Pharmaceuticals, Inc. · 1 U.S. investigator

    $4,143research payments

  46. Open- Label Trial of Sipuleucel-T Administered to Active Surveillance Patients for Newly Diagnosed Prostate Cancer

    Completed · Phase 3 · Adenocarcinoma of the Prostate

    NCT03686683 · Dendreon Pharmaceuticals LLC · 1 U.S. investigator

    $4,092research payments

  47. A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors

    Active, not recruiting · Phase 1 · Cancer

    NCT03893955 · AbbVie Inc. · 3 U.S. investigators

    $4,065research payments

  48. A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC)

    Terminated · Phase 2 · Colitis, Ulcerative

    NCT04677179 · Eli Lilly and Company · 1 U.S. investigator

    $4,059research payments

  49. A Study To Assess the Safety of OnabotulinumtoxinA (BOTOX) Intramuscular Injection in Adult Participants With Platysma Prominence

    Completed · Phase 3 · Platysma Prominence

    NCT05134649 · AbbVie Inc. · 1 U.S. investigator

    $4,000research payments

  50. A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

    Completed · Phase 2 · Prostate Cancer

    NCT02985957 · E.r. Squibb & Sons, L.l.c. · 2 U.S. investigators

    $3,947research payments

Sources: CMS Open Payments research payments, program year 2025 (trials with a ClinicalTrials.gov number), and ClinicalTrials.gov (U.S. National Library of Medicine). Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally.

About this page

Industry-funded clinical trials test new drugs and devices in patients. This list shows trials for which drug and device companies reported research payments to CMS, linked to their ClinicalTrials.gov records. For each trial, you can see the sponsor, phase and status, the U.S. physicians named as principal investigators, and how much the company paid for the research.

How to search industry-funded clinical trials

First, search by drug, condition or company. Then open a trial to see its investigators and study sites. You can also start from a doctor’s page, which lists the trials that doctor helps lead. In addition, drug and specialty pages link to the trials in their field.

What the payments mean

Research payments usually go to hospitals and universities to run the study. In other words, the money pays for the research, not the investigator personally. Companies report these payments under the federal Sunshine Act, and CMS publishes them in Open Payments (opens in a new tab). However, a payment record alone does not show how a study was run or what it found.

Joining a clinical trial

If you want to join a trial, start with the official record on ClinicalTrials.gov (opens in a new tab). It lists who can take part, where and how to contact the study team. Also talk to your doctor first, because a trial may not be right for you.

Related: Medicare drugs, drug company payments to doctors, specialties.

Questions about industry-funded clinical trials

Are industry-funded clinical trials safe? Every trial in the U.S. needs approval from an ethics board, and drug trials also follow FDA rules. However, every trial carries some risk. So read the consent form carefully and ask questions.

Who is a principal investigator? The principal investigator is the doctor who leads the study at a site. Their page here shows their other trials and the payments companies reported for that research.

Why are some trials missing? We list trials with industry research payments in Open Payments. As a result, trials funded only by the government or universities do not appear.